Search Results - "Milind, Javle"

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma by King, Gentry, Javle, Milind

“…Purpose of Review Cholangiocarcinoma is an aggressive cancer with a poor prognosis and limited treatment. Gene sequencing studies have identified genetic…”
Get full text

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma by Chun, Yun Shin, Javle, Milind

“…Intrahepatic cholangiocarcinoma represents the second most common primary liver cancer and is increasing in incidence. Most patients are diagnosed at an…”
Get full text

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation by Krishnan, Sunil, MD, Chadha, Awalpreet S., MD, Suh, Yelin, PhD, Chen, Hsiang-Chun, PhD, Rao, Arvind, PhD, Das, Prajnan, MD, Minsky, Bruce D., MD, Mahmood, Usama, MD, Delclos, Marc E., MD, Sawakuchi, Gabriel O., PhD, Beddar, Sam, PhD, Katz, Matthew H., MD, Fleming, Jason B., MD, Javle, Milind M., MD, Varadhachary, Gauri R., MD, Wolff, Robert A., MD, Crane, Christopher H., MD

“…Purpose To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with…”
Get full text

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study by Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Fan, Bin, Wu, Bin, Chamberlain, Christina X, Jiang, Liewen, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Zhu, Andrew X

“…Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a…”
Get full text

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study by Javle, Milind, Borad, Mitesh J, Azad, Nilofer S, Kurzrock, Razelle, Abou-Alfa, Ghassan K, George, Ben, Hainsworth, John, Meric-Bernstam, Funda, Swanton, Charles, Sweeney, Christopher J, Friedman, Claire F, Bose, Ron, Spigel, David R, Wang, Yong, Levy, Jonathan, Schulze, Katja, Cuchelkar, Vaikunth, Patel, Arisha, Burris, Howard

“…Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the…”
Get full text

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline by Balaban, Edward P, Mangu, Pamela B, Khorana, Alok A, Shah, Manish A, Mukherjee, Somnath, Crane, Christopher H, Javle, Milind M, Eads, Jennifer R, Allen, Peter, Ko, Andrew H, Engebretson, Anitra, Herman, Joseph M, Strickler, John H, Benson, 3rd, Al B, Urba, Susan, Yee, Nelson S

“…To provide evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer. American…”
Get full text

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers by Singhi, Aatur D., George, Ben, Greenbowe, Joel R., Chung, Jon, Suh, James, Maitra, Anirban, Klempner, Samuel J., Hendifar, Andrew, Milind, Javle M., Golan, Talia, Brand, Randall E., Zureikat, Amer H., Roy, Somak, Schrock, Alexa B., Miller, Vincent A., Ross, Jeffrey S., Ali, Siraj M., Bahary, Nathan

“…It has been a challenge to select treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted…”
Get full text

Molecular profiling of biliary tract cancer: a target rich disease by Jain, Apurva, Javle, Milind

“…Biliary tract cancers (BTCs) are relatively uncommon orphan tumors that have an aggressive disease course and a poor clinical outcome. Surgery is the only…”
Get full text

Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference by Sapisochin, Gonzalo, Javle, Milind, Lerut, Jan, Ohtsuka, Masayuki, Ghobrial, Mark, Hibi, Taizo, Kwan, Nancy Man, Heimbach, Julie

“…Liver transplantation for cholangiocarcinoma has been an absolute contraindication worldwide due to poor results. However, in recent years and thanks to…”
Get full text

Biliary cancer: Utility of next‐generation sequencing for clinical management by Javle, Milind, Bekaii‐Saab, Tanios, Jain, Apurva, Wang, Ying, Kelley, Robin Katie, Wang, Kai, Kang, Hyunseon C., Catenacci, Daniel, Ali, Siraj, Krishnan, Sunil, Ahn, Daniel, Bocobo, Andrea Grace, Zuo, Mingxin, Kaseb, Ahmed, Miller, Vincent, Stephens, Philip J., Meric‐Bernstam, Funda, Shroff, Rachna, Ross, Jeffrey

“…BACKGROUND Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit. METHODS Hybrid…”
Get full text

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial by Shroff, Rachna T, Javle, Milind M, Xiao, Lianchun, Kaseb, Ahmed O, Varadhachary, Gauri R, Wolff, Robert A, Raghav, Kanwal P S, Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K, Ahn, Daniel H, Bekaii-Saab, Tanios S, Borad, Mitesh J

“…Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and…”
Get more information

Ramucirumab: successfully targeting angiogenesis in gastric cancer by Javle, Milind, Smyth, Elizabeth C, Chau, Ian

“…Gastric cancer is the fourth most common cancer globally and represents the second most common cause of cancer-related mortality. Early detection, aggressive…”
Get full text

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies by Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L

“…The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an…”
Get full text

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis by Tao, Randa, Krishnan, Sunil, Bhosale, Priya R, Javle, Milind M, Aloia, Thomas A, Shroff, Rachna T, Kaseb, Ahmed O, Bishop, Andrew J, Swanick, Cameron W, Koay, Eugene J, Thames, Howard D, Hong, Theodore S, Das, Prajnan, Crane, Christopher H

“…Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective. Advances in radiotherapy (RT) techniques and image guidance…”
Get full text

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice by Jain, Apurva, Kwong, Lawrence N, Javle, Milind

“…Opinion statement Biliary tract cancers are relatively uncommon, have an aggressive disease course and a dismal clinical outcome. Until recently, there have…”
Get full text

Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer by Javle, Milind, Li, Yanan, Tan, Dongfeng, Dong, Xiaoqun, Chang, Ping, Kar, Siddhartha, Li, Donghui

“…Transforming growth factor (TGF)-β signaling pathway, may act both as a tumor suppressor and as a tumor promoter in pancreatic cancer, depending on tumor stage…”
Get full text

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Hong, Theodore S, Wo, Jennifer Y, Yeap, Beow Y, Ben-Josef, Edgar, McDonnell, Erin I, Blaszkowsky, Lawrence S, Kwak, Eunice L, Allen, Jill N, Clark, Jeffrey W, Goyal, Lipika, Murphy, Janet E, Javle, Milind M, Wolfgang, John A, Drapek, Lorraine C, Arellano, Ronald S, Mamon, Harvey J, Mullen, John T, Yoon, Sam S, Tanabe, Kenneth K, Ferrone, Cristina R, Ryan, David P, DeLaney, Thomas F, Crane, Christopher H, Zhu, Andrew X

“…To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma…”
Get full text

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial by Zhu, Andrew X, Macarulla, Teresa, Javle, Milind M, Kelley, R Kate, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V T, Borad, Mitesh J, Bridgewater, John A, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan R, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Chamberlain, Christina X, Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Abou-Alfa, Ghassan K

“…Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial,…”
Get more information

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression by CRANE, Christopher H, VARADHACHARY, Gauri R, DAS, Prajnan, LEE, Jeffrey E, ABBRUZZESE, James L, WOLFF, Robert A, YORDY, John S, STAERKEL, Gregg A, JAVLE, Milind M, SAFRAN, Howard, HAQUE, Waqar, HOBBS, Bridgett D, KRISHNAN, Sunil, FLEMING, Jason B

“…This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and…”
Get full text

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications by Churi, Chaitanya R, Shroff, Rachna, Wang, Ying, Rashid, Asif, Kang, HyunSeon C, Weatherly, Jacqueline, Zuo, Mingxin, Zinner, Ralph, Hong, David, Meric-Bernstam, Funda, Janku, Filip, Crane, Christopher H, Mishra, Lopa, Vauthey, Jean-Nicholas, Wolff, Robert A, Mills, Gordon, Javle, Milind

“…Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS)…”
Get full text